FAM89A

Across TCGA pan-cancer cohorts, FAM89A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM89A data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM89A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM89A expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where FAM89A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.139	0.979	.001	22	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.935	.033	3	view →
LSCC	DFS	Median	All	0.975	0.896	.031	3	view →
LUAD	DFS	Tertile	II,III,IV	0.335	0.678	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM89A–CCRCC (DFS)

Open the CCRCC breakdown →